Drug Trial Radar · NCT06605599
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
161
Actual
Start
Oct 15, 2024
Primary completion
Nov 12, 2025
Study completion Dec 10, 2025
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how safe and effective ABBV-932 is in treating participants with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Study doctors put participants in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that a participant will be assigned to placebo. Around 160 adult participants with bipolar I or II disorder will be enrolled in approximately 40 sites worldwide. Participants will receive oral capsules of ABBV-932 or matching placebo once daily for 6 weeks. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Bipolar I Disorder
- Bipolar II Disorder
Interventions
ABBV-932Drug
Oral Capsule
Placebo for ABBV-932Drug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total ScoreTime frame: Up to Week 6
Locations
40 sites in 3 countries. Site status is shown where the registry gives one.
Harmonex /ID# 267504
Dothan, Alabama
Advanced Research Center /ID# 267716
Anaheim, California
Axiom Research /ID# 267518
Colton, California
Collaborative Neuroscience Research - Garden Grove /ID# 267654
Garden Grove, California
Sun Valley Research Center /ID# 267708
Imperial, California
Alliance for Research Alliance for Wellness /ID# 267492
Long Beach, California
Excell Research /ID# 267541
Oceanside, California
Viking Clinical Research Center - Temecula /ID# 267634
Temecula, California
Accel Research Sites Network - St. Pete /ID# 267463
Largo, Florida
GMI Florida - Central Miami Medical Institute /ID# 267566
Miami, Florida
Allied Biomedical Res Inst Inc /ID# 267481
Miami, Florida
K2 Medical Research - Orlando - South Orlando Avenue /ID# 267567
Orlando, Florida
Segal Trials - West Broward Outpatient Research Site /ID# 267947
Tamarac, Florida
Benchmark Research /ID# 267626
Shreveport, Louisiana
CenExel /ID# 267675
Gaithersburg, Maryland
Arch Clinical Trials /ID# 267507
St Louis, Missouri
Duplicate_Oasis Clinical Research, LLC /ID# 267969
Las Vegas, Nevada
Center For Emotional Fitness - Cherry Hill /ID# 267661
Cherry Hill, New Jersey
Bio Behavioral Health /ID# 267493
Toms River, New Jersey
Neurobehavioral Research /ID# 267564
Cedarhurst, New York
New Hope Clinical Research - Inpatient unit /ID# 267465
Charlotte, North Carolina
Quest Therapeutics of Avon Lake /ID# 267558
Avon Lake, Ohio
OSU Psychiatry Department /ID# 267730
Columbus, Ohio
Sooner Clinical Research /ID# 267639
Oklahoma City, Oklahoma
Lehigh Center for Clinical Research /ID# 267451
Allentown, Pennsylvania
Suburban Research Associates - Media /ID# 267621
Media, Pennsylvania
Coastal Carolina Research Center, LLC /ID# 267550
Charleston, South Carolina
FutureSearch Trials of Dallas /ID# 267715
Dallas, Texas
Perceptive Pharma Research /ID# 267563
Richmond, Texas
Grayline Research Center /ID# 267466
Wichita Falls, Texas
Northwest Clinical Research Center /ID# 267505
Bellevue, Washington
Core Clinical Research /ID# 268534
Everett, Washington
Kaku Mental Clinic /ID# 268020
Fukuoka, Fukuoka, Japan
Kuramitsu Hospital /ID# 268751
Fukuoka, Fukuoka, Japan
Kokura Mental Clinic /ID# 268031
Kitakyushu, Fukuoka, Japan
Kawamura Mental Clinic /ID# 268325
Sapporo, Hokkaido, Japan
Yutaka Clinic /ID# 268026
Sagamihara, Kanagawa, Japan
INSPIRA Clinical Research /ID# 267041
San Juan, Puerto Rico, Puerto Rico
Instituto De Neurologia Dra. Ivonne Fraga, Psc /ID# 267065
San Juan, Puerto Rico, Puerto Rico
BDH Research /ID# 267025
San Juan, Puerto Rico, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.